3.58

0.56% 0.02

Onkure Therapeutics Inc (OKUR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$3.56

Offen:

$3.53

24-Stunden-Volumen:

165.54K

Relative Volume:

0.57

Marktkapitalisierung:

$144.98M

Einnahmen:

Nettoeinkommen (Verlust:

$-58.75M

KGV:

-0.8274

EPS:

-4.327

Netto-Cashflow:

$-50.79M

1W Leistung:

-5.54%

1M Leistung:

-12.68%

6M Leistung:

+12.93%

1J Leistung:

+33.09%

1-Tages-Spanne:

$3.5075

$3.62

1-Wochen-Bereich:

$3.41

$3.8999

52-Wochen-Spanne:

$2.23

$5.38

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Firmenname

Onkure Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(720) 307-2892

Adresse

6707 WINCHESTER CIRCLE, SUITE 400, BOULDER

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

OKUR's Discussions on Twitter

Compare OKUR vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OKUR Onkure Therapeutics Inc	3.58	159.15M	0	-58.75M	-50.79M	-4.327
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-30	Eingeleitet	Evercore ISI	Outperform
2024-12-05	Eingeleitet	Leerink Partners	Outperform
2024-10-10	Eingeleitet	Oppenheimer	Outperform
2023-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-12-15	Herabstufung	Jefferies	Buy → Hold
2023-12-15	Herabstufung	Leerink Partners	Outperform → Market Perform
2023-12-14	Herabstufung	BofA Securities	Buy → Underperform
2023-12-14	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2023-12-14	Herabstufung	Piper Sandler	Overweight → Neutral
2023-12-14	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-12-14	Herabstufung	William Blair	Outperform → Mkt Perform
2023-11-15	Eingeleitet	William Blair	Outperform
2023-08-28	Eingeleitet	H.C. Wainwright	Buy
2023-07-03	Eingeleitet	BofA Securities	Buy
2022-09-19	Fortgesetzt	H.C. Wainwright	Buy
2022-01-27	Eingeleitet	Robert W. Baird	Outperform
2021-12-21	Eingeleitet	H.C. Wainwright	Buy
2021-11-22	Eingeleitet	Ladenburg Thalmann	Buy
2021-05-04	Eingeleitet	Jefferies	Buy
2021-05-04	Eingeleitet	Piper Sandler	Overweight
2021-05-04	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten

Aug 14, 2026

Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus

Aug 14, 2026

OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan

Aug 14, 2026

OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan

Aug 14, 2026

OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan

Aug 14, 2026

Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com

Aug 14, 2026

Aug 13, 2026

OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn

Aug 13, 2026

OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet

Aug 13, 2026

OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks

Aug 13, 2026

Aug 10, 2026

Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan

Aug 10, 2026

Aug 08, 2026

OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et

Aug 08, 2026

Aug 07, 2026